Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 6/20 | 0.44 |
| ▸ | FNTB | P49356 | 6/20 | 0.44 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31683255 | 0.90 | FNTA (0.41) | FNTAFNTBPGGT1B | |
| SCHEMBL29406776 | 0.90 | FNTA (0.43) | FNTAFNTBPGGT1BOPRM1OPRD1 | |
| SCHEMBL31276516 | 0.90 | FNTA (0.44) | FNTAFNTBPGGT1BOPRM1OPRD1 | |
| SCHEMBL29375582 | 0.85 | DPP4 (0.47) | OPRM1OPRD1DPP4DPP8DPP9 | |
| SCHEMBL29630546 | 0.85 | BACE1 (0.42) | FNTAFNTBDPP4DPP8DPP9 | |
| SCHEMBL30596284 | 0.83 | OPRM1 (0.50) | OPRM1OPRD1KEAP1 | |
| SCHEMBL17867385 | 0.82 | FNTA (0.44) | FNTAFNTBPGGT1B | |
| SCHEMBL17867383 | 0.82 | FNTA (0.44) | FNTAFNTBPGGT1B | |
| SCHEMBL29815915 | 0.81 | OPRM1 (0.50) | OPRM1OPRD1 | |
| SCHEMBL30272493 | 0.80 | FNTA (0.44) | FNTAFNTBPGGT1BOPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146247-A1 | Compositions and Methods for Targeted Delivery of CRISPR-CAS Effector Polypeptides and Transgenes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-28 | — | — | US | disclosed |
| US-12624063-B2 | Compositions and methods for modification of target molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260109753-A1 | Syntac Polypeptides and Uses Thereof | ALBERT EINSTEIN COLLEGE MEDICINE (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260070959-A1 | T-Cell Modulatory Chimeric Molecules and Methods of Use Thereof | CUE BIOPHARMA INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12565647-B2 | Compositions and methods for targeted delivery of CRISPR-Cas effector polypeptides and transgenes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-03-03 | — | — | US | disclosed |
| US-20260015381-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF TARGET MOLECULES | UNIV CALIFORNIA (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260008996-A1 | Compositions and Methods for Modification of Cells | UNIV CALIFORNIA (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250288672-A1 | HUMANIZED SYNTHETIC NOTCH RECEPTORS WITH AUGMENTED TRANSACTIVATION DOMAINS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-09-18 | — | — | US | disclosed |
| US-20250289885-A1 | ENGINEERED PROTEASE ACTIVITY RESPONSIVE RECEPTORS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250243257-A1 | BINDING-TRIGGERED TRANSCRIPTIONAL SWITCHES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-07-31 | — | — | US | disclosed |
| CN-114728173-A | Novel receptors with heterologous stop transfer sequences for ligand-dependent transcriptional regulation | 加利福尼亚大学董事会 | 2022-07-08 | — | — | CN | disclosed |
| CN-114728174-A | Receptors with heterologous transmembrane domains | 加利福尼亚大学董事会 | 2022-07-08 | — | — | CN | disclosed |
| CN-114728172-A | Notch receptors with minimal linkers | 加利福尼亚大学董事会 | 2022-07-08 | — | — | CN | disclosed |
| CN-114729025-A | Novel receptors for ligand-dependent transcriptional regulation | 加利福尼亚大学董事会 | 2022-07-08 | — | — | CN | disclosed |
| US-11358995-B2 | Compositions and methods of use for treating metabolic disorders | NGM BIOPHARMACEUTICALS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| CN-114599674-A | T cell modulating chimeric molecules and methods of use thereof | 库尔生物制药有限公司 | 2022-06-07 | — | — | CN | disclosed |
| US-20220153779-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF TARGET MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-05-19 | — | — | US | disclosed |
| CN-106687128-B | Compositions and methods for treating metabolic disorders | NGM生物制药有限公司 | 2022-05-10 | — | — | CN | disclosed |
| US-20220133797-A1 | NOTCH RECEPTORS WITH HINGE DOMAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-05-05 | — | — | US | disclosed |
| CN-106573966-B | Compositions and methods for treating metabolic abnormalities | NGM生物制药有限公司 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070959-A1 | T-Cell Modulatory Chimeric Molecules and Methods of Use Thereof | ICOS, ICOSLG, CD274 | FNTA 4720/4885FNTB 3439/4885PGGT1B 3499/4885 |
| US-20260109753-A1 | Syntac Polypeptides and Uses Thereof | ICOS, CD40LG, CD40 | FNTA 3831/4885FNTB 2495/4885PGGT1B 4398/4885 |
| US-12624063-B2 | Compositions and methods for modification of target molecules | TYR, TH, COMT | FNTA 3042/4885FNTB 1415/4885PGGT1B 3758/4885 |
| US-20260015381-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF TARGET MOLECULES | TH, COMT, TYR | FNTA 4461/4885FNTB 3500/4885PGGT1B 4224/4885 |
| US-20260008996-A1 | Compositions and Methods for Modification of Cells | CD2, CD47, EPCAM | FNTA 3652/4885FNTB 2735/4885PGGT1B 2946/4885 |
| US-20250289885-A1 | ENGINEERED PROTEASE ACTIVITY RESPONSIVE RECEPTORS AND USES THEREOF | NOTCH1, ADAM17, ADAM33 | FNTA 1244/4885FNTB 716/4885PGGT1B 1828/4885 |
| US-12565647-B2 | Compositions and methods for targeted delivery of CRISPR-Cas effector polypeptides and transgenes | CD4, PBK, HAVCR2 | FNTA 4018/4885FNTB 3392/4885PGGT1B 2787/4885 |
| US-20260146247-A1 | Compositions and Methods for Targeted Delivery of CRISPR-CAS Effector Polypeptides and Transgenes | LNPEP, PRNP, CPSF1 | FNTA 3360/4885FNTB 3192/4885PGGT1B 2852/4885 |
| US-20220153779-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF TARGET MOLECULES | COMT, TH, AOX1 | FNTA 1682/4885FNTB 1433/4885PGGT1B 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.